



NEWS RELEASE

Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience

2026-10-27

Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry

TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of internationally recognized leaders in stem cell biology, regenerative medicine, neuroscience and small molecule chemistry who will help guide the company's long-term scientific exploration of regeneration, aging and neurodegenerative biology.

"Much of my scientific career has been devoted to understanding how cellular polarity governs stem cell function and tissue regeneration," said Michael Rudnicki, OC, FRS, co-founder and chief discovery officer. "We are only beginning to appreciate how these fundamental biological processes may influence aging, neurodegeneration and other conditions beyond muscle disease. I am thrilled to welcome this remarkable group of scientists to our SAB and look forward to exploring new scientific questions that could deepen our understanding of regenerative biology."

The Board will advise on emerging discoveries in stem cell biology, molecular signaling and disease pathology, including how aging influences regenerative capacity and how mechanisms governing stem cell behavior may contribute to neurodegenerative disease.

"We are honored to bring together this exceptional group of scientists to serve on Satellos' Scientific Advisory Board," said Satellos Chief Scientific Officer Phil Lambert, Ph.D. "The SAB will help deepen our understanding of how

cellular polarity influences tissue maintenance, regeneration and disease across multiple biological systems. Its collective expertise will broaden our scientific perspective as we explore aging and neuroscience and continue advancing our understanding of regenerative biology."

The members of the Satellos SAB are:

- Janet Rossant, CC, Ph.D., FRS, FRSC, Chief of Research Emeritus and Senior Scientist Emeritus, The Hospital for Sick Children (Satellos SAB Chair)
- Rima Al-awar, Ph.D., Vice Provost, Research Innovations and Commercialization, New York University Abu Dhabi
- Sebastian Jessberger, M.D., Professor of Neurosciences and Director, Brain Research Institute, University of Zurich
- Mary Mader, Ph.D., President, MM Molecular Pharma Consulting LLC
- Lee Rubin, Ph.D., Professor of Stem Cell and Regenerative Biology, Harvard University; Co-director, Harvard Stem Cell Institute
- Marius Wernig, M.D., Ph.D., Professor of Pathology and Chemical and Systems Biology, Stanford University

Full biographies of the Scientific Advisory Board members are available on the **Company's website**.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment for Duchenne muscular dystrophy (DMD) in two Phase 2 clinical trials, BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD. The FDA also cleared an Investigational New Drug (IND) application for the clinical evaluation of forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit **www.satellos.com** and connect with Satellos on **X, LinkedIn, Facebook** and **Instagram**.

NOTICE ON FORWARD-LOOKING STATEMENTS

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the possibility of pursuing regulatory approval for forazapadin, including a potential accelerated approval pathway; anticipated benefits to patients from forazapadin; the enrollment in, advancement and timing of results of forazapadin through clinical trials, including the BASECAMP, TRAILHEAD and Phase 2 FSHD clinical trials, and the

timing of release of related clinical trial data; the potential of Satellos' approach in other degenerative muscle diseases and Satellos' plans to pursue additional muscle diseases and injury conditions in future clinical development; Satellos' technologies and drug development plans; and Satellos' expectation for broader use of International Nonproprietary Name in future scientific, regulatory and corporate communications. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are "forward-looking information or statements." Often, but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "believe", "plan", "expect", "intend", "estimate", "anticipate", "potential", "prospective", "assert" or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. In making forward looking statements, the Company has relied on various assumptions, including but not limited to: its ability to obtain future funding on favorable terms, if at all; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the "Risk Factors" section of Satellos' Annual Information Form dated March 27, 2026, and amended and restated short form base shelf prospectus dated August 11, 2026 (each of which is located on Satellos' SEDAR+ profile) and incorporated by reference in Satellos' Form F-10 filed with the Securities and Exchange Commission on August 11, 2026, and in Satellos' public filings on EDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.

CONTACTS

Investors: Caitlin Lowie, Vice President, Investor Relations & Communications, ir@satellos.com

Media: Emily Williams, Senior Director, Communications, media@satellos.com

Source: Satellos Bioscience Inc.